Eli Lilly and Co

George Frey | Bloomberg | Getty ImagesWeight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. Demand for the drugs is unlikely to slow down in 2024, especially as treatments gradually become more accessible. Much of Wall Street believes the weight loss drug market will only expand,…

Eli Lilly's drug tirzepatide was approved for weight loss by the FDA.Courtesy of Eli LillyPatients who took Eli Lilly's weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. The data, which represents the full results from an 88-week study funded by Eli Lilly, suggests that people have to stay on the weekly injection if they want to maintain significant weight loss.Shares of Eli Lilly fell more than 3% Monday after the…

President Joe Biden speaks about protecting Social Security, Medicare, and lowering prescription drug costs, during a visit to OB Johnson Park and Community Center, in Hallandale Beach, Florida, on Nov. 1, 2022.Kevin Lamarque | ReutersThe Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.The administration unveiled a framework outlining the factors federal agencies should consider in…

The FDA approves Eli Lilly's Zepbound, a weight loss drug similar to Ozempic and Wegovy.Courtesy: Eli LillyEli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. Zepbound is the latest entrant to the budding weight loss drug market, which Wall Street expects to grow to about $100 billion by the end of the decade.High demand for the treatments has resulted in…

Sopa Images | Lightrocket | Getty ImagesPfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug lost significant weight but experienced high rates of adverse side effects in a midstage clinical trial. Pfizer noted that it will release data on a once-daily version of…

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant share of patients also stopped taking the drug in the trial."At this time, twice-daily danuglipron formulation will not advance into Phase 3 studies," the company…

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August 31, 2023.Victoria Klesty | ReutersNovo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and "potentially unsafe" drugs claiming to contain semaglutide, the active ingredient in the drugmaker's blockbuster weight loss treatment Wegovy and diabetes medication Ozempic. The actions come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in…

A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023.George Frey | ReutersThe blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday.Patients taking Eli Lilly's Mounjaro were significantly more likely to lose weight and saw larger reductions in…

CFOTO | Future Publishing | Getty ImagesAs its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer's experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space's dominant players Eli Lilly and Novo Nordisk.Those companies helped spark the weight loss drug industry gold rush over the last year with their weekly obesity and diabetes injections, such as Novo Nordisk's Wegovy and Ozempic and…

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesThe Food and Drug Administration on Wednesday approved Eli Lilly's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.But the FDA's new approval means adults who have obesity or are overweight…